Where Can You Get Immunotherapy for Non-Small Cell Lung Cancer in India in 2026?
Introduction
The financial shock of a non-small cell lung cancer (NSCLC) diagnosis is often measured in the gap between what a prescription demands and what a family can afford. You are staring at a treatment that promises to turn your own immune system against the tumor, but you cannot find a clear answer on where to actually get it, what it costs, or whether the logistics will break you before the disease does. In August 2026, the Drug Controller General of India (DCGI) approved subcutaneous atezolizumab (Tecentriq SC), a formulation that condenses an hours-long intravenous infusion into a roughly seven-minute injection, eliminating the need for an infusion chair altogether. This article maps out exactly where that therapy and other approved checkpoint inhibitors are delivered across India, breaks down the real costs per dose, and walks you through the testing, visa, and support infrastructure you need to move from diagnosis to treatment without being crushed by uncertainty.
Key Takeaways
Immunotherapy for NSCLC in India now includes both intravenous and a newly approved seven-minute subcutaneous option, delivered across a network of government and private tertiary centres. Here are the key facts you need before you move forward:
Approved drugs available: DCGI-approved immune checkpoint inhibitors include atezolizumab (IV and SC), nivolumab, and pembrolizumab, accessible at major centres across the country.
Hard cost benchmark: Tecentriq SC is priced at approximately ₹3.7 lakh per 21-day dose, with comparable pricing structures for other agents in this class.
Cost-reduction evidence: A landmark 2022 Indian trial demonstrated that ultra-low-dose nivolumab (6% of the standard dose) doubled one-year survival, where 43% in the immunotherapy group versus 16% in the control group were alive at one year.
Candidacy requires testing: PD-L1 expression and tumor mutational burden (TMB) testing on biopsy tissue are key to determine whether you are likely to respond.
Medical visa mandatory: International patients must secure a medical visa and coordinate through hospital international patient desks for invitation letters and FRRO registration.
What Is Immunotherapy for Non-Small Cell Lung Cancer?
Immunotherapy for NSCLC is not chemotherapy and it is not a direct cell poison. It is a treatment that removes the camouflage your cancer cells use to hide from your own T-cells. NSCLC tumors often exploit a checkpoint pathway (PD-1/PD-L1) to send a "do not attack" signal to your immune system.
Drugs called immune checkpoint inhibitors, including atezolizumab, nivolumab, and pembrolizumab, physically block that signal. When the blockade is in place, your cytotoxic T-cells can recognize the NSCLC cells as foreign and mount an attack. This mechanism is fundamentally different from chemotherapy, which kills rapidly dividing cells indiscriminately.
In the adjuvant setting, checkpoint inhibitors are used after surgery and chemotherapy to clear residual microscopic disease in early-stage NSCLC. In the metastatic setting, they are the backbone of treatment for patients whose tumors do not harbor targetable driver mutations like EGFR or ALK. Do not start immunotherapy until a thorough biomarker panel on your biopsy tissue is complete.
Approved Immunotherapy Drugs for NSCLC in India
The DCGI has cleared several immune checkpoint inhibitors for NSCLC in India, and as of 2026, the landscape includes both standard intravenous formulations and a transformative subcutaneous option. Atezolizumab (Tecentriq) is now available in two forms: the original IV infusion and the newly launched Tecentriq SC, a subcutaneous injection approved in August 2026 for adjuvant and metastatic NSCLC. Nivolumab and pembrolizumab remain widely prescribed intravenous PD-1 inhibitors accessible at most tertiary cancer centres.
The most consequential Indian evidence for nivolumab comes from a 2022 phase 3 trial that tested a dose just 6% of the standard US and European regimen. In that study of advanced head and neck cancer patients, one-year survival was 43% for the ultra-low-dose immunotherapy group compared to 16% for standard treatment. Tumors also shrank or stopped growing for 59% of people on immunotherapy versus 45% in the control arm.
This dose reduction has enormous implications for affordability, because it demonstrates that durable oncologic benefit is achievable at a fraction of the conventional pricing. While this trial was in head and neck cancer, the pharmacologic principle is being actively explored in NSCLC, and many Indian oncologists are comfortable discussing off-label low-dose nivolumab protocols in resource-constrained situations where standard dosing is financially inaccessible.
Pembrolizumab-based perioperative protocols are also validated by global trial data. The KEYNOTE-671 trial demonstrated a significant improvement in event-free survival when pembrolizumab combined with chemotherapy was given both before and after surgery for early-stage NSCLC, and it was the first perioperative immunotherapy trial in early-stage lung cancer to show an overall survival benefit. Under the trial protocol, patients received four cycles of chemotherapy plus pembrolizumab prior to surgery, followed by adjuvant pembrolizumab.
Leading Hospitals and Cancer Centres Providing NSCLC Immunotherapy in India
Roche launched India's first seven-minute subcutaneous atezolizumab (Tecentriq SC) in May 2026, and the delivery map is shifting fast. Swiss pharma giant Roche launches India's first seven-minute under-the-skin lung cancer drug Not every centre that runs IV immunotherapy has adopted the shorter protocol yet, so which chair you sit in and how long you stay depends more on the hospital's workflow than on the drug's existence.
Tata Memorial in Mumbai is a government quaternary referral centre that handles an enormous NSCLC volume through disease management groups, each one staffed by clinicians dedicated to a single cancer type. It delivers IV checkpoint inhibitors (atezolizumab, nivolumab, pembrolizumab) and expects to fold in SC atezolizumab. International Patients, T.M.C.
Medanta in Gurugram built a domestic CAR-T cell program and now offers the full IV checkpoint inhibitor line plus the Tecentriq SC seven-minute protocol. Its thoracic tumor boards coordinate immunotherapy decisions. Manipal Hospital in Bangalore runs both IV and subcutaneous immunotherapy and has tuned its infusion-chair logistics and observation periods for rapid delivery.
The HCG network operates oncology centres in Bengaluru, Ahmedabad, Mumbai, Kolkata, and other cities, with IV checkpoint inhibitors listed as a core program. SC availability varies by unit; confirm it before you book. Immunotherapy Treatment in India | HCG
Diagnostic depth differs considerably. Tata Memorial runs thorough in-house PD-L1 IHC testing and next-generation sequencing. Medanta offers full biomarker testing including PD-L1 TPS and TMB. Manipal does PD-L1 testing and molecular profiling on-site. At HCG, diagnostic services differ by centre, so verify the NSCLC biomarker panel before scheduling.
The table below lays out institutional type, immunotherapy delivery method, disease management model, international patient infrastructure, and diagnostic capability side by side.
Feature | Tata Memorial Hospital, Mumbai | Medanta, Gurugram | Manipal Hospital, Bangalore | HCG Network (Multi-City) |
Institutional type | Government-run quaternary referral centre; among the oldest and largest cancer centres globally | Private multi-specialty with a domestically developed CAR-T cell program | Private multi-specialty tertiary hospital | Private oncology chain with centres in Bengaluru, Ahmedabad, Mumbai, Kolkata, and other cities |
Immunotherapy delivery | IV checkpoint inhibitors including atezolizumab, nivolumab, and pembrolizumab; SC atezolizumab integration expected | Full range of IV checkpoint inhibitors; subcutaneous atezolizumab (Tecentriq SC) 7-minute protocol | IV and subcutaneous immunotherapy available with infusion-chair and rapid-delivery observation logistics | IV checkpoint inhibitors listed as a core oncology program; verify SC availability at your specific centre |
Disease management model | Specialized Disease Management Groups (DMGs), each composed of dedicated clinicians for a specific cancer type | Multi-disciplinary tumor boards for thoracic oncology | Multi-disciplinary lung cancer unit with access to supportive and integrative care | Thoracic oncology department with multi-disciplinary care coordination |
International patient infrastructure | Dedicated International Patients Advisor office; medical reports and treatment summaries required for initiation; 'F Category' charges apply | Dedicated international desk issuing one-year medical visa invitation letters, assisting with FRRO registration, and coordinating airport pickups | International patient coordination with virtual pre-travel consultation availability | Multi-city presence allows geographic flexibility; verify international desk services at the specific hospital unit |
Diagnostic capability | Comprehensive in-house PD-L1 IHC testing and next-generation sequencing | Full biomarker testing including PD-L1 TPS and TMB | PD-L1 testing and molecular profiling on-site | Diagnostic services vary by centre; confirm NSCLC biomarker panel availability before scheduling |
How Much Does Immunotherapy for NSCLC Cost in India?
Tecentriq SC is priced at approximately ₹3.7 lakh per dose, administered once every 21 days, putting a standard course of adjuvant or maintenance therapy well into the tens of lakhs for patients paying out of pocket. This is the current reference price for subcutaneous checkpoint inhibitor access in India for 2026, and it applies whether you are at a government or private hospital, because the drug cost itself does not vary dramatically by institution, though professional fees and facility charges do.
International pricing puts this in sharp relief.
The ultra-low-dose nivolumab strategy, where researchers validated a dose at 6% of the American and European standard, offers a concrete path to affordability. The study showed a clear overall survival benefit at a fraction of the cost, and many Indian medical oncologists in high-volume centres are willing to adopt this approach in NSCLC when standard dosing is financially out of reach and the patient's clinical profile supports it.
Dr. Bharat Patodiya's practice provides upfront cost estimates and financial counseling for lung cancer treatment, including chemotherapy packages starting at ₹2.5 to 8 lakhs with supportive care, and transparent pricing models starting at ₹3,000 for three-month subscription support programs, helping you model total expenditure before you commit.
How to Determine If You Are a Candidate: Biomarker and PD-L1 Testing
You need a PD-L1 tumor proportion score (TPS) and tumor mutational burden (TMB) result from your biopsy tissue before an oncologist can responsibly prescribe a checkpoint inhibitor. These tests quantify how actively your cancer cells are using the PD-1/PD-L1 checkpoint to hide, and they are the strongest predictors of whether immunotherapy will produce a durable response or simply expose you to toxicity and financial drain without benefit. A retrospective analysis of 24,152 advanced NSCLC patients found that the combination of high TMB and high PD-L1 expression was the strongest predictor of durable response, with an odds ratio of 0.04.
High PD-L1 expression, defined as 50% or greater tumor cell staining, was independently associated with checkpoint inhibitor response. Standard blood tests like albumin and lymphocyte counts were merely prognostic, correlating with outcomes regardless of whether you receive immunotherapy or chemotherapy, and therefore cannot tell you whether immunotherapy specifically will help.
You can get PD-L1 immunohistochemistry and thorough genomic profiling done at Tata Memorial Hospital in Mumbai, which houses India's largest oncology tissue bank, or at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) in Navi Mumbai. Most private chains including HCG and Medanta also perform these assays on-site with turnaround times under a week for the immunohistochemistry component.
The field is not without controversy. The Australian Medical Services Advisory Committee concluded in 2022 that PD-L1 is a poor biomarker, with a real likelihood that patients who might benefit from checkpoint inhibitors would be excluded by a negative test result. Analytical performance is degraded by different test protocols, intra-tumor heterogeneity, and inter-observer variability. You should therefore interpret a borderline or negative PD-L1 result in the context of your full clinical picture, including TMB and your performance status, rather than treating it as a definitive gate that locks you out of immunotherapy.
Accessing Treatment as an International Patient: Visas, Consultations, and Coordination
You must secure a medical visa before traveling to India for NSCLC immunotherapy, and this process begins not at the embassy but at the hospital. Contact the international patient desk at your chosen centre, upload your medical reports including biopsy confirmation of NSCLC, imaging, and treatment summaries, and request a medical visa invitation letter. The hospital will issue a letter specifying the proposed treatment plan and duration, which you then submit with your visa application. Once you arrive in India, the same international desk assists with Foreigners Regional Registration Office (FRRO) registration within the mandated 14-day window and coordinates airport pickup if arranged in advance. Dr. Bharat Patodiya's practice connects patients with dedicated international desks that issue one-year medical visa invitation letters, assist with FRRO registration, and coordinate airport pickups, streamlining the administrative pathway before you leave home.
Lock in a virtual consultation before you fly. Most major centres now offer telemedicine second-opinion access where an Indian medical oncologist reviews your biomarker report and scans remotely, confirms your candidacy, and gives you a preliminary treatment schedule and cost estimate. Tata Memorial, Medanta, and the HCG network run established tele-oncology portals for this. The consultation prevents you from arriving only to discover that your tumor biology does not support immunotherapy or that an important biopsy slide needs to be re-cut.
Supportive Care and Reducing the Treatment Burden
The shift from an hours-long intravenous infusion to a seven-minute subcutaneous injection changes the lived experience of lung cancer treatment, but the full supportive care infrastructure around that injection determines whether you can stay on therapy without cumulative physical and psychological erosion. Here is what you should demand from your centre:
Rapid-delivery observation protocols: Tecentriq SC administration takes roughly seven minutes, cutting chair time to a fraction of conventional IV checkpoint inhibitor delivery and freeing you from prolonged infusion-centre stays that amplify anxiety and fatigue.
Integrative oncology and side-effect management: Centers like Dr.Bharat Patodiya use multidisciplinary teams that combine evidence-based complementary therapies with standard immunotherapy. You get acupuncture for chemotherapy-related nausea and neuropathy, nutritional counseling tailored to your metabolic status, and psycho-oncology support for decision-making distress.
Nutrition and pain management access: You need a dedicated supportive care unit that addresses malabsorption, cancer cachexia, and immunotherapy-related pain through specialized palliative care coordination, not a generic referral that leaves you navigating these specialties on your own.
Psychological and family support: The compassionate care model at thorough Indian cancer centres includes family education programs and both individual and group psychological support. The emotional burden of a stage IV NSCLC diagnosis is the most common reason patients discontinue therapy even when it is working.
Conclusion
In 2026, a patient with non-small cell lung cancer can move from an uploaded biopsy report to an immunotherapy appointment on a defined timeline. India offers the anti-PD-L1 subcutaneous checkpoint inhibitor approved by the Drugs Controller General of India, a published ultra-low-dose strategy with survival data, and centres that handle international patients end to end.
Book a virtual consultation to get a candidacy assessment and a real-world cost estimate. The seven-minute injection is waiting on the other side of your medical visa invitation letter and locked travel dates.
Frequently Asked Questions
Which hospitals and cancer centres in India offer immunotherapy for non-small cell lung cancer (NSCLC)?
Tata Memorial Hospital in Mumbai, Medanta in Gurugram, Manipal Hospital in Bangalore, and the HCG network across multiple cities all administer checkpoint inhibitors for NSCLC. Each has a thoracic oncology unit and international patient desk, though delivery models and SC atezolizumab availability vary.
What specific immunotherapy drugs or checkpoint inhibitors are approved and available for NSCLC treatment in India?
The DCGI has approved atezolizumab (both IV and subcutaneous Tecentriq SC), nivolumab, and pembrolizumab for NSCLC. Atezolizumab SC launched in August 2026. Ultra-low-dose nivolumab protocols at 6% of the standard dose are also clinically utilized in some Indian centres.
How much does immunotherapy for non-small cell lung cancer cost in India?
The current benchmark is approximately ₹3.7 lakh per 21-day dose of Tecentriq SC. Ultra-low-dose nivolumab can significantly reduce cost and still demonstrated a doubled one-year survival rate in an Indian phase 3 trial. Additional hospital and professional fees apply and vary by institution.
What is the process for an international patient to access immunotherapy for NSCLC in India, including medical visas and virtual consultations?
You must first contact the hospital's international desk to obtain a medical visa invitation letter. Upload your medical reports and schedule a virtual consultation before traveling. After arrival, the hospital assists with FRRO registration, airport pickup, and treatment scheduling.
How do I find out if I am a candidate for immunotherapy for my NSCLC (biomarker testing like PD-L1)?
You need PD-L1 immunohistochemistry (TPS) and tumor mutational burden (TMB) testing on your biopsy tissue. Major centres like Tata Memorial, ACTREC, Medanta, and HCG perform these assays. High PD-L1 (≥50%) and high TMB together are the strongest predictors of a durable response.
What supportive care and integrative oncology services are available alongside immunotherapy for lung cancer patients in India?
Indian cancer centres provide nutrition counseling for cachexia, pain and palliative care management, psycho-oncology support for anxiety, and acupuncture for neuropathy and nausea. Multidisciplinary teams coordinate these services, and new SC delivery further eases the burden by cutting chair time drastically.
Sources
Low Dose of Cancer Immunotherapy Effective in Trial in India - NCI - www.cancer.gov
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC - PMC - pmc.ncbi.nlm.nih.gov
Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data - PubMed - pubmed.ncbi.nlm.nih.gov
International Patients - T.M.C. - tmc.gov.in
Redefining care for early-stage lung cancer with immunotherapy combo | Stanford Cancer Institute - med.stanford.edu
Immunotherapy Treatment in India | HCG - www.hcgoncology.com
Swiss pharma giant Roche launches India’s first seven-minute under-the-skin lung cancer drug - www.newindianexpress.com
Comments